Impact of Vaccination on Major Adverse Cardiovascular Events in Patients With COVID-19 Infection

Jiang, Joy X.; Chan, Lili; Kauffman, Justin; Narula, Jagat; Charney, Alexander; Oh, Won-Suk; Nadkarni, Girish N.

doi:10.1016/j.jacc.2022.12.006

Cited by 24 publications

(21 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Vaccination against SARS-CoV-2 has clearly reduced the occurrence of myocardial infarction and stroke after COVID-19 [1622,1623]. These data should not be interpreted as to mean that the vaccine has a specific CV protective effect.…”

Section: Hypertension and Other Selected Comorbiditiesmentioning

confidence: 88%

“…Indeed, a rise in office [1616,1619] and home [1620] BP, as well as an increase in the proportion of patients with uncontrolled hypertension [1620] has been observed during the pandemic, albeit not consistently in all studies [1621]. 20.9.3 Vaccination against SARS-CoV-2 and hypertension Vaccination against SARS-CoV-2 has clearly reduced the occurrence of myocardial infarction and stroke after COVID-19 [1622,1623]. These data should not be interpreted as to mean that the vaccine has a specific CV protective effect.…”

Section: Covid-19 Lockdown and Hypertension Managementmentioning

confidence: 99%

See 1 more Smart Citation

2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension

Chairperson

Co-Chair

Brunström

et al. 2023

Journal of Hypertension

719

280

View full text Add to dashboard Cite

Document Reviewers: Luis Alcocer (Mexico), Christina Antza (Greece), Mustafa Arici (Turkey), Eduardo Barbosa (Brazil), Adel Berbari (Lebanon), Luís Bronze (Portugal), John Chalmers (Australia), Tine De Backer (Belgium), Alejandro de la Sierra (Spain), Kyriakos Dimitriadis (Greece), Dorota Drozdz (Poland), Béatrice Duly-Bouhanick (France), Brent M. Egan (USA), Serap Erdine (Turkey), Claudio Ferri (Italy), Slavomira Filipova (Slovak Republic), Anthony Heagerty (UK), Michael Hecht Olsen (Denmark), Dagmara Hering (Poland), Sang Hyun Ihm (South Korea), Uday Jadhav (India), Manolis Kallistratos (Greece), Kazuomi Kario (Japan), Vasilios Kotsis (Greece), Adi Leiba (Israel), Patricio López-Jaramillo (Colombia), Hans-Peter Marti (Norway), Terry McCormack (UK), Paolo Mulatero (Italy), Dike B. Ojji (Nigeria), Sungha Park (South Korea), Priit Pauklin (Estonia), Sabine Perl (Austria), Arman Postadzhian (Bulgaria), Aleksander Prejbisz (Poland), Venkata Ram (India), Ramiro Sanchez (Argentina), Markus Schlaich (Australia), Alta Schutte (Australia), Cristina Sierra (Spain), Sekib Sokolovic (Bosnia and Herzegovina), Jonas Spaak (Sweden), Dimitrios Terentes-Printzios (Greece), Bruno Trimarco (Italy), Thomas Unger (The Netherlands), Bert-Jan van den Born (The Netherlands), Anna Vachulova (Slovak Republic), Agostino Virdis (Italy), Jiguang Wang (China), Ulrich Wenzel (Germany), Paul Whelton (USA), Jiri Widimsky (Czech Republic), Jacek Wolf (Poland), Grégoire Wuerzner (Switzerland), Eugene Yang (USA), Yuqing Zhang (China).

show abstract

Section: Hypertension and Other Selected Comorbiditiesmentioning

confidence: 88%

Section: Covid-19 Lockdown and Hypertension Managementmentioning

confidence: 99%

2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension

Chairperson

Co-Chair

Brunström

et al. 2023

Journal of Hypertension

719

280

View full text Add to dashboard Cite

show abstract

“…Importantly, the IAMI trial demonstrated the safety of administering IV in patients at the time of acute atherothrombotic events, allowing for opportunistic vaccination of at‐risk individuals while they are hospitalized. Furthermore, emerging evidence suggests that COVID‐19 vaccination is associated with a reduced risk of MACE compared to unvaccinated individuals, albeit in non‐randomized cohort studies 8 . The advancements in messenger ribonucleic acid (mRNA) and viral vector deoxyribonucleic acid (DNA) vaccines developed during the COVID‐19 pandemic hold promise for the future of influenza prevention, potentially revolutionizing the approach to influenza vaccine development.…”

Section: Figurementioning

confidence: 99%

“…Furthermore, emerging evidence suggests that COVID-19 vaccination is associated with a reduced risk of MACE compared to unvaccinated individuals, albeit in non-randomized cohort studies. 8 The advancements in messenger ribonucleic acid (mRNA) and viral vector deoxyribonucleic acid (DNA) vaccines developed during the COVID-19 pandemic hold promise for the future of influenza prevention, potentially revolutionizing the approach to influenza vaccine development.…”

mentioning

confidence: 99%

Influenza vaccination: Simple, safe, and effective for patients with ischaemic heart disease and heart failure

Brennan

Campbell

Lee

2023

European J of Heart Fail

View full text Add to dashboard Cite

“…Studies of the effects of COVID-19 vaccination status on development of Long COVID or persistence of COVID-19 symptoms have primarily focused on two comparisons: 1) difference in outcome rate or probability between people who were unvaccinated at time of COVID-19 infection versus those people who were vaccinated (in some form) prior to having a COVID-19 infection [6,[10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27] and 2) difference in outcome rate or probability between people who were unvaccinated at time of COVID-19 infection versus those people who were vaccinated after having a COVID-19 infection [28][29][30][31][32][33][34][35][36][37][38]. Though see Simon et al [39] for an example of an analysis of the effect of vaccination on the development of Long COVID which considers vaccination before and after COVID-19 infection.…”

Section: Introductionmentioning

confidence: 99%

Effect of vaccination on time till Long COVID, a comparison of two ways to model effect of vaccination and two outcome definitions

Smits

Rodriguez

Gratzl

et al. 2023

Preprint

View full text Add to dashboard Cite

Long COVID, or post-COVID syndrome, is a constellation of symptoms observed in patients at least four weeks after COVID-19 infection. We analyzed the effect of COVID-19 vaccination status on risk of either developing Long COVID symptoms or being diagnosed with Long COVID. In separate analyses we compared the effect of vaccination status at time of COVID-19 infection and the effect of vaccination status as a time-dependent covariate where vaccination could occur at any point with respect to COVID-19 infection. To address this question, we identified a subset of adult patients from Truveta Data who experienced a COVID-19 infection as indicated by a positive laboratory test between 2021-10-01 and 2022-11-31. We considered two distinct ways of modeling the effect of vaccination status (time-independent and time-dependent) and two distinct outcomes of interest (Long COVID symptoms or diagnosis with Long COVID), representing four distinct analyses. The presence of Long COVID symptoms was defined as the presence of one or more new symptoms consistent with COVID-19/Long COVID at least four weeks post COVID-19 infection. Diagnosis of Long COVID was determined by the presence of one or more ICD-10-CM or SNOMED-CT codes explicitly identifying a patient as having been diagnosed with Long COVID. Our analysis focusing on the effect of COVID-19 vaccination status at time of COVID-19 infection found that patients who had completed a primary COVID-19 vaccination sequence or had completed a primary vaccination sequence and received a booster dose at time of COVID-19 infection were on average at lower risk of either developing Long COVID symptoms or being diagnosed with Long COVID than unvaccinated patients (vaccinated versus unvaccinated HR of symptoms 0.9 [0.87-0.94], HR of diagnosis 0.86 [0.74-0.99]; vaccinated and boosted versus unvaccinated HR of symptoms 0.87 [0.83-0.91], HR of diagnosis 0.81 [0.69-0.95]). We do not find evidence that having received a booster dose in addition to having completed a primary vaccination sequence offers additional protection over having completed the primary sequence alone (vaccinated and boosted versus vaccinated HR of symptoms 0.96 [0.91-1.01], HR of diagnosis 0.94-1.13) . Our analysis of COVID-19 vaccination status modeled as a time-dependent covariate yielded similar results for patients who had completed a primary COVID-19 vaccination sequence or had completed a primary vaccination sequence and a booster dose. Both groups were on average at lower risk of developing Long COVID symptoms or being diagnosed with Long COVID than patients who where never vaccinated (vaccinated versus unvaccinated HR of symptoms 0.91 [0.88-0.95], HR of diagnosis 0.86 [0.75-0.99]; vaccinated and boosted versus unvaccinated HR of symptoms 0.88 [0.85-0.91], HR of diagnosis 0.77 [0.67-0.9]). As with the time-independent analysis, we also find that having completed a booster dose in addition to a primary COVID-19 vaccination sequence does not provide additional protection from developing Long COVID symptoms or being diagnosed with Long COVID over having completed the primary sequence alone (vaccinated and boosted versus vaccinated HR of symptoms 0.96 [0.92-1.01], HR of diagnosis 0.89 [0.76-1.06]) . We find that completing a primary vaccination sequence is associated with a decreased risk of developing Long COVID symptoms or being diagnosed with Long COVID compared with no vaccination regardless of whether vaccination status is modeled as a time-independent or time-dependent covariate. We find a similar protective effect in patients who have completed a primary vaccination sequence and a booster dose when compared to the those who are unvaccinated. However, we do not find evidence for a difference in protective effect between patients who have completed a primary vaccination sequence and a booster dose and those patients who have only completed a primary vaccination sequence. Our results support the growing evidence that having complete a primary vaccination sequence is protective against the development of Long COVID symptoms or the diagnosis of Long COVID.

show abstract

Impact of Vaccination on Major Adverse Cardiovascular Events in Patients With COVID-19 Infection

Cited by 24 publications

References 5 publications

2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension

2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension

Influenza vaccination: Simple, safe, and effective for patients with ischaemic heart disease and heart failure

Effect of vaccination on time till Long COVID, a comparison of two ways to model effect of vaccination and two outcome definitions

Contact Info

Product

Resources

About